78 results about "Cell Proliferative Activity" patented technology

The invention provides humanized recombinant XVII collagen for promoting hair follicle stem cell repair and resisting aging as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The humanized recombinant XVII type collagen comprises polypeptide derived from the XVII type collagen or repeated protein formed by N times of repeated series connection of the polypeptide serving as a unit, n is an integer from 2 to 4; the polypeptide derived from the XVII type collagen comprises a polypeptide A and / or a polypeptide B; the amino acid sequence of the A polypeptide is as shown in SEQ ID NO: 1; and the amino acid sequence of the B polypeptide is as shown in SEQ ID NO: 2. The humanized recombinant XVII type collagen not only can be massively and stably recombined and expressed, but also has cell adhesion activity, cell proliferation promotion activity, cell migration promotion activity and excellent hair follicle repair and regeneration promotion activity, and has no sensitization side effect. The invention provides a new way for preparing collagen products with rich functions.

The invention discloses recombinant human I-type collagen and application thereof. The amino acid sequence of the recombinant human I-type collagen is as shown in SEQ ID No: 2. The recombinant human I-type collagen has good cell proliferation promoting activity, cell migration promoting activity and cell adhesion promoting activity (superior to full-length recombinant human I-type collagen or commercially available human collagen) and is easy to produce. The recombinant human I-type collagen can be expected to have the effects of whitening, moisturizing, relieving and repairing, and can be applied to the fields of cosmetics, external medicines, skin care products, health care products, tissue engineering materials, medical instruments and the like.

The invention discloses a recombinant fibronectin fusion protein and application thereof. The recombinant fibronectin fusion protein comprises a recombinant fibronectin mutant (FN1) and a platelet factor 4 (PF4), the amino acid sequence of the recombinant fibronectin is as shown in SEQ ID NO. 3 or SEQ ID NO. 4. The molecular weight of the recombinant fibronectin fusion protein is less than 90KDa, and the recombinant fibronectin fusion protein is good in solubility, simple in preparation process and convenient to purify; the recombinant fibronectin provided by the invention has novel recombinant fibronectin, and can inhibit inflammation in a wound healing process, so that mouse skin injury healing is efficiently promoted, and a new thought can be provided for development of wound healing drugs. In addition, when the platelet factor 4 is creatively fused to the N end of the fibronectin mutant, the cell proliferation activity can be obviously and effectively promoted.

The invention discloses recombinant IV-type collagen as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the recombinant IV type collagen comprises a plurality of repetitive units, and the repetitive units are shown as SEQ ID NO. 1. The recombinant IV type collagen fragment is derived from human IV type collagen, heterologous amino acid residues are not introduced, and rejection and sensitization risks are avoided; meanwhile, the hydrogel also has good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, and is good in biocompatibility. In addition, the preparation method of the recombinant IV-type collagen is simple and easy to operate, and the recombinant IV-type collagen with high purity and stability can be obtained through the fermentation and purification method. Therefore, the recombinant IV type collagen disclosed by the invention has a relatively good application prospect.

The invention discloses a preparation method and application of recombinant humanized III-type collagen, and belongs to the technical field of genetic engineering. According to the invention, three segments with good hydrophilicity and high solubility are screened from a humanized III-type collagen sequence through a bioinformatics method, and coding genes of the three segments are integrated into a pichia pastoris genome in a multi-copy form after being subjected to pichia pastoris codon preference optimization, so that a recombinant strain of the humanized III-type collagen is obtained. The recombinant strain secretes and expresses collagen, the purity can reach 95% or above only through one-step purification, the downstream separation and purification difficulty is obviously reduced, and the production process is easy to amplify. The prepared three recombinant human-derived III-type collagen proteins all have the activity of promoting cell migration and the activity of promoting cell proliferation, and have good application value.

The invention discloses application of a host factor MOV10 in development of rabies treatment medicines and vaccine production, and belongs to the technical field of biological medicines. In order to research the influence of the host factor MOV10 on the replication of the RABV, the invention discovers that the overexpression host factor MOV10 coding gene can inhibit the replication of the RABV through the technologies of real-time fluorescent quantitative PCR (Polymerase Chain Reaction), Western Blotting, direct immunofluorescence and the like; then, a mov10 gene knockout cell line is successfully constructed through a CRISPR / Cas9 gene editing technology, the cell proliferation activity of the mov10 gene knockout cell line and the influence of the mov10 gene knockout cell line on RABV replication are researched, and it is found that stable knockout of the mov10 gene can remarkably promote replication of RABV CVS11 and SRV9. Technical support is provided for exploration of MOV10 biological functions and development and production of RABV inactivated vaccines and recombinant virus vaccines with RABV as carriers.

The invention belongs to the technical field of medicinal chemistry, and discloses a paeonol mannich base-rhein conjugate as well as a preparation method and application thereof. The conjugate is a compound as shown in a general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically common antitumor drugs fluorouracil and paeonol, the conjugate provided by the invention has obviously higher in-vitro anti-human hepatoma carcinoma cell (HepG2) and human lung cancer cell (A549) proliferative activity, and the in-vitro anti-human cervical carcinoma cell (Hela), human colon cancer cell (HT29) and human osteosarcoma cell (U2OS) proliferative activity of most compounds is obviously superior to that of fluorouracil and paeonol; and the conjugate has good water solubility, is expected to be applied to treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has a wide clinical application prospect. # imgabs0 #

The invention relates to the technical field of molecular biology, and particularly discloses application of miR-615 in ovarian granular cells. The miR-615 is applied to any one of the following items: preparing a product for promoting the activity and / or proliferation of ovarian granular cells; preparing a product for promoting generation of estradiol and / or progesterone; preparing a product for promoting the expression of the 3 beta-HSD and / or StAR gene; preparing a product for inhibiting ACSL4 gene expression; and preparing a product competitively combined with the lnc-GAM. According to the invention, porcine ovarian granular cells are used as a material, the expression level of lnc-GAM-miR-615 / ACSL4 regulatory axis is up-regulated or down-regulated in the porcine ovarian granular cells by using gene overexpression and interference technologies, and the expression of the lnc-GAM-miR-615 / ACSL4 regulatory axis is determined by detecting cell proliferation activity, hormone secretion level and apoptosis gene expression in combination with a dual-luciferase reporter gene test. And the regulation effect of lnc-GAM mediation on the apoptosis of the porcine ovarian granular cells is researched.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention discloses a synthetic method of a C1-triazole oridonin derivative and an anti-tumor application of the C1-triazole oridonin derivative. The invention provides a synthetic method of the C1-triazole oridonin derivative, which comprises the following steps: carrying out four-step reaction to obtain an oridonin analogue containing an azide group at the C1 site, and catalyzing by cuprous iodide to obtain the C1-triazole oridonin derivative with the azide group at the C1 site, thereby obtaining the C1-triazole oridonin derivative with the azide group at the C1 site and the oridonin analogue with the azide group at the C1 site. According to the method, alkyne compounds containing different substituent groups react with C1-triazole oridonin to synthesize the C1-triazole oridonin derivative, the method is mild in condition and rapid in reaction, large-scale preparation of the C1-triazole oridonin derivative can be achieved, and the method is suitable for large-scale production of the C1-triazole oridonin derivative. Meanwhile, the C1-triazole oridonin derivative synthesized by the invention can be used for effectively inhibiting the proliferation activity of tumor cells and has a relatively good inhibition effect on MCF-7 cells and A549 cells.

The invention discloses application of phloretin in preparation of a medicine for promoting liver cell proliferation, and belongs to the technical field of medicine. A specific cell proliferation tracing system of the hepatocytes is utilized, the proliferation activity of the hepatocytes in an animal body can be continuously recorded, animal experiments find that in the physiological homeostasis maintaining process of a mouse, phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of liver tissue, and it is found through hepatic lobule zoning analysis that phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of the liver tissue. The phloretin can effectively promote proliferation of hepatic cells in the first, second and third regions of the hepatic lobule. Therefore, phloretin is a potential medicine for liver regeneration.

The invention belongs to the technical field of organoids, and particularly relates to a method for evaluating the influence of intervention measures such as drugs on the proliferation capacity of intestinal stem cells through proliferation indexes of the organoids and application of the method. The invention discloses a kit for efficiently, simply, conveniently and effectively culturing and constructing intestinal organs and evaluating the multiplication capacity of intestinal stem cells, which can better fit in-vivo tissues and cell microenvironments, as well as a method and application of the kit. The method can be used for detecting the influence of different intervention measures on the proliferation activity of the small intestine stem cells more accurately and more stably, and is beneficial to deeply researching and developing new drugs and researching the drug sensitivity and the drug action mechanism.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The present invention belongs to the technical field of pharmaceutical chemistry, and discloses a paeonol Mannich base-rhein conjugate, a preparation method thereof and an application thereof. The conjugate is a compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically commonly used anti-tumor drugs fluorouracil and paeonol, the conjugate of the present invention has significantly higher in vitro proliferation inhibitory activities against human liver cancer cells (HepG2) and human lung cancer cells (A549), and the in vitro proliferation inhibitory activities of most compounds against human cervical cancer cells (Hela), human colon cancer cells (HT29) and human osteosarcoma cells (U2OS) are significantly better than those of fluorouracil and paeonol, indicating excellent anti-tumor effects. Moreover, the conjugate of the present invention has good water solubility and is expected to be applied to the treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has broad clinical application prospects.

The invention discloses a polypeptide, a recombinant XI type humanized collagen formed by the polypeptide and application of the recombinant XI type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the recombinant humanized polypeptide is designed and prepared on the basis of a natural XI type collagen core functional area, and the polypeptide can form a stable triple-helix structure. The recombinant XI type humanized collagen provided by the invention has good biological activities, including promotion of cell proliferation activity, promotion of cell adhesion activity and promotion of extracellular matrix generation or reconstruction, and is suitable for various medical or non-medical applications.

The invention discloses hydrogel loaded with repair-promoting and antioxidant peptides as well as a preparation method and application of the hydrogel, and belongs to the technical field of preparation of medical materials. According to the preparation method, firstly, polypeptide with the amino acid sequence of CEYWVKWCGEKGPAGERG is synthesized, and the polypeptide has antioxidant activity and cell proliferation promoting activity and has good structural stability and enzymatic degradation resistance; and loading the polypeptide into the hyaluronic acid hydrogel to obtain the hyaluronic acid hydrogel. The prepared hydrogel loaded with the repair-promoting and antioxidant peptide has excellent injectable performance and cornea spreadability, can enhance the retention of the polypeptide on the ocular surface, effectively solves the technical problem of high administration frequency of the existing preparation, has good cell and tissue compatibility, and has no adverse reaction in vivo.

This invention relates to the field of biotechnology, specifically disclosing a novel polypeptide, recombinant XIX type humanized collagen, and their applications. This invention provides a novel polypeptide with good cell adhesion activity and the ability to promote cell proliferation. The amino acid sequence of the polypeptide comprises n repeating units; each repeating unit comprises any one of the following (1)-(3) amino acid sequences or their variants: (1) the amino acid sequence shown in SEQ ID NO.1; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO.1; (3) a variant sequence obtained by mutating one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; wherein n ≥ 1 and is an integer. The polypeptide of this invention can be used in various fields such as promoting skin barrier repair, wound healing, and epidermal renewal.

A microneedle loaded with at least curcumin, exosomes, and an acellular matrix. Curcumin is incorporated into the exosomes to form functionalized exosomes (Cur@EV), which serve as the primary active ingredient for the repair of hypertrophic scars. Cur@EV has been shown to exhibit a high affinity for hypertrophic scar fibroblasts, while more efficient delivery of curcumin to HSFs has demonstrated enhanced anti-HSF cell proliferation activity and significant anti-fibrosis effects, potentially meeting clinical needs for the repair of hypertrophic scars.

The invention belongs to the technical field of organic synthesis, and specifically relates to a method for preparing a pyridoimidazole nitrogen condensed ring compound, comprising: using a substituted chromone and a substituted 2-aminopyridine as raw materials, adding an oxidant and a catalyst, and reacting in a solvent to obtain a pyridoimidazole nitrogen condensed ring compound; the substituted 2-aminopyridine contains a group R 1 , substituted chromones contain a group R 2 , R 1 is selected from one of an alkyl group, a hydrogen group, a halogen group, an ester group, a methanol group, a trifluoromethyl group and a cyano group, R 2 is selected from one of alkyl, hydrogen, methoxy and halogen, R 1 and R 2 The substitution modes are all single substitution or multiple substitution. The preparation method of the present invention is simple and safe to operate, the cost of raw materials is low, and the scope of application is wide. In addition, the pyridine imidazole nitrogen fused ring compound of the present invention has a novel structure, has anti-MV4-11 cell proliferation activity, and can be used in the preparation of leukemia drugs.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The present invention discloses a methylidene-modified calix[3]carbazole derivative and its preparation method and application, belonging to the field of medical technology. The methylidene-modified calix[3]carbazole derivative of the present invention has a general structural formula as shown in formula (II); in formula (II), R4, R5, and R6 are each independently selected from one of hydroxyl, C1-C3 alkoxy, amino-substituted C1-C5 alkoxy, benzylamino, hydrazine, fatty amine containing O atoms, fatty amine containing N atoms, or ethoxy. The methylidene-modified calix[3]carbazole derivative of the present invention has good activity in inhibiting tumor cell proliferation and has good development prospects in the preparation of anti-tumor drugs.

The invention discloses a method for purifying a recombinant human basic fibroblast growth factor (bFGF). Relates to the technical field of biology. Comprising the following steps: inducing expression of bFGF; soluble protein extraction and primary purification; carrying out primary heparin affinity chromatography purification; the enterokinase of the bFGF trx tag is cut off; and carrying out secondary heparin affinity chromatography purification. The purification process is optimized, so that the product recovery rate is remarkably improved, and the method has the advantage of high large-scale production. The purified bFGF shows remarkable biological activity in a cell proliferation activity experiment; a dose-dependent proliferation promoting effect is shown in a concentration range of 1-10ng / mL; when the concentration is 10ng / mL, the cell proliferation reaches 3.2 + / -0.4 times. Besides, through systematic expression optimization and an innovative purification process, efficient preparation of the high-activity bFGF protein is realized, and a high-quality raw material is provided for the fields of tissue repair and regenerative medicine.

The invention discloses a medicine composition for treating tumors and inflammation and application thereof. The medicine composition has a synergistic effect when used in a combined mode, and the anti-tumor effect, the anti-inflammation effect and the like can be enhanced. According to the application, a cell proliferation activity detection method and a real-time fluorescent quantitative detection method are used for evaluating the combined use of the target compound naringin dihydrochalcone and the antitumor drug cis-platinum, and the result shows that compared with the single use of one of the drugs, the combined use has better mouse monocyte leukemia cell proliferation resistance; and the expression of related inflammatory factors in an LPS-induced cell inflammation model can be obviously inhibited. The invention provides a group of pharmaceutical compositions which have better anti-tumor and anti-inflammatory effects.

The present invention relates to an edible medium composition having excellent cell proliferation activity. The edible medium composition according to the present invention has the effect of improving cell proliferation activity and inhibiting cellular senescence. In addition, the edible medium of the present invention is literally composed of raw materials that are edible for humans, and thus can be advantageously used as a culture medium for cell-cultured foods. Cells cultured in the edible medium composition of the present invention exhibit higher food safety while also offering cost advantages, compared to cells cultured in conventional media.

This invention is to provide a means capable of providing excellent cell proliferation activity to a hydrophilic polymer substrate. Provided is a cell culture substrate comprising a coating layer on at least one surface of a hydrophilic polymer substrate, wherein the coating layer includes a polymer comprising a structural unit derived from furfuryl (meth)acrylate represented by Formula, and a ratio of mass of the polymer contained per unit area of the coating layer is more than 2 μg / cm2.

The invention relates to the technical field of biology, in particular to desmosome-XVII type collagen fusion protein as well as a preparation method and application thereof. The invention provides a recombinant XVII type collagen fusion protein which comprises at least one XVII type collagen functional domain fragment and at least one functional domain fragment of desmosome core glycoprotein, the recombinant human X VII type collagen fusion protein provided by the invention has better cell adhesion activity and cell proliferation promoting activity. The recombinant human XVII type collagen fusion desmosis protein can significantly improve the adhesion between cells in a cell culture environment, and compared with commercial human XVII type collagen, the recombinant human XVII type collagen fusion desmosis protein can improve the effect by several times or more. In the aspect of promoting cell proliferation, the cell division cycle can be effectively shortened, so that the number of cells is rapidly increased within the same time, and the XVII type collagen is remarkably superior to commercial human XVII type collagen, and has wider application potential in the fields of skin care products, cosmetics, medicines, biomedical materials and the like.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. According to the invention, through a large number of screening researches, a core functional region of a natural human XI type collagen alpha1 (XI) chain and a natural human XI type collagen alpha2 (XI) chain of a recombinant XI type humanized collagen with a triple helix structure can be formed in an in-vitro biosynthesis process. Furthermore, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The invention provides an application of a PARP1 inhibitor in preparation of a medicine for treating and / or relieving Friedel's ataxia, and belongs to the technical field of medicines. According to the application disclosed by the invention, B lymphocyte GM15850 and / or fibroblast GM03816 from a Friedel's Ataxia (FRDA) patient are / is taken as a research object, and the PARP1 inhibitor is verified to have the effects of remarkably improving cell proliferation and activity, and can be used for promoting the expression of cell mitochondria FXN protein and promoting the activity of a mitochondria compound; an FRDA mouse model YG8R is used as a research object, and it is verified that the PARP1 inhibitor can remarkably improve the movement function of mice and improve the FXN protein level of all tissues of the mice. The PARP1 inhibitor has the effect of treating and / or relieving FRDA, and can be applied to preparation of drugs for treating and / or relieving FRDA related diseases.